{"id":"https://openalex.org/W2090657374","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-147","title":"Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.","display_name":"Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2090657374","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-147","mag":"2090657374"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2013-lb-147","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-147","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-lb-147","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103514741","display_name":"Jeffrey R. Infante","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey R. Infante","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012216189","display_name":"Leena Gandi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leena Gandi","raw_affiliation_strings":["2Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey Shapiro","raw_affiliation_strings":["2Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075877134","display_name":"Naiyer A. Rizvi","orcid":"https://orcid.org/0000-0002-1134-7494","observed_orcids":["https://orcid.org/0000-0002-1134-7494"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naiyer Rizvi","raw_affiliation_strings":["3Memorial Sloan-Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Memorial Sloan-Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johanna C. Bendell","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose\u0301 Baselga","raw_affiliation_strings":["4Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072906560","display_name":"Karl Hsu","orcid":"https://orcid.org/0000-0003-3137-1202","observed_orcids":["https://orcid.org/0000-0003-3137-1202"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karl Hsu","raw_affiliation_strings":["5Sanofi, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Sanofi, Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022988657","display_name":"Oliver von Richter","orcid":"https://orcid.org/0000-0002-5262-9922","observed_orcids":["https://orcid.org/0000-0002-5262-9922"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Oliver von Richter","raw_affiliation_strings":["6Global Exploratory Medicine, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Global Exploratory Medicine, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001666583","display_name":"Giuseppe Locatelli","orcid":"https://orcid.org/0000-0002-2179-4407","observed_orcids":["https://orcid.org/0000-0002-2179-4407"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Giuseppe Locatelli","raw_affiliation_strings":["7Global Research & Early Development, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Global Research & Early Development, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108297819","display_name":"Ekaterine Asatiani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113211","display_name":"Merck Serono S.A. (Switzerland)","ror":"https://ror.org/01vp49361","country_code":"CH","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210113211"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ekaterine Asatiani","raw_affiliation_strings":["8Merck Serono S.A. \u2013 Geneva, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Merck Serono S.A. \u2013 Geneva, Geneva, Switzerland","institution_ids":["https://openalex.org/I4210113211"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064382279","display_name":"Rebecca Suk Heist","orcid":"https://orcid.org/0000-0002-7397-2009","observed_orcids":["https://orcid.org/0000-0002-7397-2009"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca S. Heist","raw_affiliation_strings":["4Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"73","issue":"8_Supplement","first_page":"LB","last_page":"147"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pimasertib","display_name":"pimasertib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.8579999804496765},{"id":"https://openalex.org/keywords/pi3k-mtor-inhibitors","display_name":"PI3K/mTOR inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.722000002861023},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8289999961853027},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7540000081062317},{"id":"https://openalex.org/keywords/pi3k-mtor-signaling","display_name":"PI3K/mTOR signaling","score":0.8650000095367432},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8679999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9039999842643738},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8040000200271606},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9419999718666077},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.4560000002384186}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8110042810440063},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6540659666061401},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5745845437049866},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.567134439945221},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5158704519271851},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.48145025968551636},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4498509466648102},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4492295980453491},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4342949390411377},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4338165521621704},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3975295126438141},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3633090853691101},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.09786340594291687},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.09591737389564514},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2013-lb-147","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-147","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-lb-147","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3012385461","https://openalex.org/W2956607982","https://openalex.org/W2588419540","https://openalex.org/W2905870549","https://openalex.org/W1996458873","https://openalex.org/W2899848123","https://openalex.org/W2265743937","https://openalex.org/W3106155507","https://openalex.org/W1592490241","https://openalex.org/W2336866290"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,129,181,226,248,330,399,408],"PI3K/mTOR":[3,39,475],"and":[4,13,36,45,70,101,126,152,173,192,223,241,243,270,278,290,306,314,323,370,390,403,410,473],"MAPK":[5],"signaling":[6],"pathways":[7,25],"are":[8,375,415],"frequently":[9],"aberrated":[10],"in":[11,76,358,478],"tumors":[12,60],"interact":[14],"to":[15],"promote":[16],"growth.":[17],"This":[18,47],"trial":[19,51],"investigated":[20],"simultaneous":[21],"inhibition":[22],"of":[23,29,64,87,97,131,179,251,401,419,423,430,467,485,494,499],"these":[24,65],"using":[26],"a":[27,143,486],"combination":[28,133,400,414],"the":[30,37,88,105,132,135,165,345,413,417,420,468,474,495,500],"selective":[31],"uncompetitive":[32],"MEK1/2":[33],"inhibitor":[34,40],"pimasertib":[35,98,353,402,471],"dual":[38],"SAR245409":[41,102,404],"(ClinicalTrials.gov":[42],"NCT01390818).":[43],"Materials":[44],"Methods:":[46],"phase":[48,347,487],"Ib,":[49],"dose-escalation":[50,489],"(modified":[52],"3+3":[53],"design)":[54],"included":[55],"patients":[56,479],"(pts)":[57],"with":[58,61,267,281,383,480],"solid":[59,482],"frequent":[62,228],"activation":[63],"pathways,":[66],"no":[67,394],"approved":[68],"therapy,":[69],"ECOG":[71,177],"performance":[72],"status":[73],"\u22641.":[74],"Expansion":[75],"selected":[77],"indications,":[78],"based":[79,351],"on":[80,352],"activity":[81,431],"signals,":[82],"was":[83,134,168,202,254,332,344],"allowed":[84],"after":[85,220,355],"determination":[86],"maximum":[89],"tolerated":[90],"dose":[91,107,137,349],"(MTD).":[92],"Pts":[93],"received":[94],"21-day":[95],"cycles":[96,253],"(once-daily,":[99],"qd)":[100],"(qd)":[103],"at":[104,138,204,378],"following":[106],"levels":[108],"(DLs):":[109],"DL1,":[110],"15/30;":[111],"DL2a,":[112],"30/30;":[113],"DL2b,":[114],"15/50;":[115],"DL3,":[116],"30/50;":[117],"DL4a,":[118],"60/50;":[119],"DL4b,":[120],"30/70;":[121],"DL5,":[122],"60/70;":[123],"DL6a,":[124],"90/70":[125],"DL6b":[127,205],"60/90.":[128],"MTD":[130,331,409],"highest":[136],"which":[139,218],"\u22641/6":[140],"pts":[141,160,208,293,373],"had":[142,175,209,212,286,294],"dose-limiting":[144],"toxicity":[145],"(DLT).":[146],"Safety,":[147],"pharmacokinetics":[148],"(PK),":[149],"pharmacodynamics":[150],"(PD)":[151],"tumor":[153,185,288],"response":[154],"were":[155,163,259],"investigated.":[156],"Results:":[157],"Of":[158],"46":[159],"treated,":[161],"57%":[162],"male,":[164],"median":[166,249],"age":[167],"58.5":[169],"years":[170],"(range":[171,256],"31-82)":[172],"54%":[174],"an":[176],"PS":[178],"1.":[180],"most":[182,227],"common":[183],"primary":[184],"types":[186],"were:":[187,234],"colorectal":[188],"(CRC,":[189,365],"n=16),":[190],"pancreatic":[191],"non-small":[193],"cell":[194],"lung":[195],"cancer":[196,277,285,322,327],"(NSCLC,":[197],"n=7,":[198],"each).":[199,247],"Dose":[200,381],"escalation":[201,382],"stopped":[203],"as":[206,426],"2/3":[207],"DLTs;":[210],"both":[211],"grade":[213,275,283],"3":[214],"nausea":[215,239],"and/or":[216],"vomiting,":[217],"resolved":[219],"supportive":[221],"care":[222],"treatment":[224],"interruption.":[225],"adverse":[229],"events":[230],"(AEs)":[231],"(all":[232],"grades)":[233],"diarrhea":[235],"(54%),":[236],"fatigue":[237],"(50%),":[238],"(41%)":[240],"vomiting":[242],"dermatitis":[244],"acneiform":[245],"(39%":[246],"number":[250],"initiated":[252],"2":[255,260],"1-16).":[257],"There":[258],"partial":[261],"responses":[262],"(KRAS":[263],"mutated":[264],"[mt]":[265],"CRC":[266],"neuro-endocrine":[268],"features":[269],"KRAS":[271,303,308,310],"mt/PIK3CA":[272],"mt":[273,311,319,325],"low":[274,282],"ovarian":[276,284],"another":[279],"pt":[280],"29%":[287],"shrinkage)":[289],"7":[291],"other":[292],"stable":[295],"disease":[296],"lasting":[297],">12":[298],"weeks":[299],"(CRC":[300],"[n=2,":[301],"1":[302,307],"wild-type":[304],"(wt)":[305],"mt];":[309],"NSCLC":[312,369],"[n=2];":[313],"BRAF":[315],"wt":[316],"melanoma,":[317,371],"KIT":[318],"soft":[320],"palate":[321],"PIK3CA":[324],"bladder":[326],"[n=1,":[328],"each]).":[329],"DL6a":[333],"(pimasertib":[334],"90":[335],"mg":[336],"/":[337],"SAR":[338],"245409":[339],"70":[340],"mg).":[341],"DL5":[342],"(60/70)":[343],"recommended":[346],"II":[348],"(RP2D)":[350],"tolerability":[354],"prolonged":[356],"exposure":[357],"monotherapy":[359],"program.":[360],"Four":[361],"disease-specific":[362],"expansion":[363],"cohorts":[364],"triple-negative":[366],"breast":[367],"cancer,":[368],"18":[372],"each)":[374],"being":[376],"treated":[377],"this":[379],"dose.":[380],"twice-daily":[384],"administration":[385],"is":[386,406],"ongoing.":[387],"Preliminary":[388],"PK":[389],"PD":[391],"data":[392],"showed":[393],"apparent":[395],"drug-drug":[396],"interaction.":[397],"Conclusions:":[398],"qd":[405],"feasible.":[407],"RP2D":[411],"for":[412,503],"within":[416],"range":[418],"active":[421],"doses":[422],"each":[424],"drug":[425],"monotherapy.":[427],"Early":[428],"signals":[429],"have":[432],"been":[433],"observed.":[434],"Citation":[435],"Format:":[436],"Jeffrey":[437],"R.":[438],"Infante,":[439],"Leena":[440],"Gandi,":[441],"Geoffrey":[442],"Shapiro,":[443],"Naiyer":[444],"Rizvi,":[445],"Howard":[446],"A.":[447],"Burris,":[448],"Johanna":[449],"C.":[450],"Bendell,":[451],"Jose\u0301":[452],"Baselga,":[453],"Karl":[454],"Hsu,":[455],"Oliver":[456],"von":[457],"Richter,":[458],"Giuseppe":[459],"Locatelli,":[460],"Ekaterine":[461],"Asatiani,":[462],"Rebecca":[463],"S.":[464],"Heist.":[465],"Combination":[466],"MEK":[469],"inhibitor,":[470,476],"(MSC1936369B),":[472],"SAR245409,":[477],"advanced":[481],"tumors:":[483],"Results":[484],"Ib":[488],"trial.":[490],"[abstract].":[491],"In:":[492],"Proceedings":[493],"104th":[496],"Annual":[497],"Meeting":[498],"American":[501],"Association":[502],"Cancer":[504,514],"Research;":[505],"2013":[506],"Apr":[507],"6-10;":[508],"Washington,":[509],"DC.":[510],"Philadelphia":[511],"(PA):":[512],"AACR;":[513],"Res":[515],"2013;73(8":[516],"Suppl):Abstract":[517],"nr":[518],"LB-147.":[519],"doi:10.1158/1538-7445.AM2013-LB-147":[520]},"counts_by_year":[{"year":2019,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}